New TB vaccine granted orphan drug status.

New TB vaccine granted orphan drug status.

Podrobná bibliografie
Hlavní autoři:	Lang, T, Hill, A, Mcshane, H, Shah, R, Towse, A, Pritchard, C, Garau, M
Médium:	Journal article
Jazyk:	English
Vydáno:	2005

Podobné jednotky

Establishing a reasonable price for an orphan drug
Autor: Mikel Berdud, a další
Vydáno: (2020-09-01)

Towards new TB vaccines
Autor: Brazier, B, a další
Vydáno: (2020)

Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB
Autor: Kalipso Chalkidou, a další
Vydáno: (2020-04-01)

TB vaccines in clinical development
Autor: Ginsberg, A, a další
Vydáno: (2016)

TB vaccines in clinical development
Autor: Ginsburg, A, a další
Vydáno: (2016)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
Autor: Mcshane, H
Vydáno: (2008)

Need for more TB vaccine field sites.
Autor: Mcshane, H
Vydáno: (2009)

Development of Orphan Vaccines: An Industry Perspective
Autor: Jean Lang, a další
Vydáno: (1999-12-01)

TB vaccines in clinical development
Autor: Ginsberg, AM, a další
Vydáno: (2016)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
Autor: Whelan, K, a další
Vydáno: (2009)

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
Autor: Minassian, A, a další
Vydáno: (2011)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
Autor: Owiafe, P, a další
Vydáno: (2012)

TB vaccine development: where are we and why is it so difficult?
Autor: Wilkie, M, a další
Vydáno: (2014)

Implementation status of pharmacological studies in the development of orphan drugs
Autor: Saki Yokoshiki, a další
Vydáno: (2024-01-01)

Progress and challenges in TB vaccine development
Autor: Voss, G, a další
Vydáno: (2018)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
Autor: Pathan, A, a další
Vydáno: (2012)

NOW THE SOLUTION IS HERE – SOCIAL ASSISTANCE FOR ORPHANED CHILDREN: THE EXTENDED CHILD SUPPORT GRANT
Autor: Sipho Sibanda, a další
Vydáno: (2023-04-01)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
Autor: Pathan, A, a další
Vydáno: (2012)

A review of clinical models for the evaluation of human TB vaccines.
Autor: O'Shea, M, a další
Vydáno: (2016)

Advances in orphan drug development: Time to change the status and stereotype
Autor: Sayanta Thakur
Vydáno: (2022-01-01)

Current status and trend of clinical development of orphan drugs in China
Autor: Ziling Xiang, a další
Vydáno: (2022-07-01)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
Autor: Ewa Stawowczyk, a další
Vydáno: (2019-11-01)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
Autor: Morrell, L, a další
Vydáno: (2017)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
Autor: Kathryn T. Whelan, a další
Vydáno: (2011-01-01)

Donor investment choices in developing countries: a methodology and some illustrative results based on Public-Private partnerships for product development (PD PPPs)
Autor: Gray, A, a další
Vydáno: (2007)

Orphan drugs and rare diseases /
Autor: Pryde, David C., editor, a další
Vydáno: (2014)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
Autor: Odutola, A, a další
Vydáno: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
Autor: Odutola, A, a další
Vydáno: (2012)

Current Status and Prospect of Orphan Drugs for Rare Skin Diseases in China
Autor: ZHANG Shan, a další
Vydáno: (2023-04-01)

Mechanism of coordinated access to orphan drugs
Autor: DeRidder R, a další
Vydáno: (2012-11-01)

International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea
Autor: Eun Young Shin, a další
Vydáno: (2024-12-01)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
Autor: Liz Morrell, a další
Vydáno: (2017-08-01)

FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
Autor: Kathleen L. Miller, a další
Vydáno: (2020-09-01)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data.
Autor: McShane, H, a další
Vydáno: (2014)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data
Autor: McShane, H, a další
Vydáno: (2014)

Rare diseases and orphan drugs.
Autor: Aronson, J
Vydáno: (2006)

Predictors of orphan drug approval
Autor: Heemstra Harald
Vydáno: (2010-10-01)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
Autor: Hans-Georg Eichler, a další
Vydáno: (2023-01-01)

Expenditure trends of orphan drugs in Serbia: 8-Year analysis of orphan drug market in Serbia
Autor: Pejčić Ana V., a další
Vydáno: (2016-01-01)

Adenylosuccinic Acid: An Orphan Drug with Untapped Potential
Autor: Emma Rybalka, a další
Vydáno: (2023-05-01)